



26th International Conference on Antiviral Research (ICAR) Preliminary Scientific Program

Saturday, May 11, 2013

- 1:30pm-3:30pm **Interactive Workshop:** Drug Discovery and Development 101
Christos Petropolous, Ph.D. (LabCorp/Monogram Biosciences) – Will be discussing the requirements for resistance testing in drug development and the use of resistance data to define a compound's mechanism of action.
James M. McKim, Ph.D., DABT (CeeTox, Inc.) – “An In Vitro Model for Identifying Heart and Liver Specific Toxicity of Antiviral Drugs”
Anthony Ham, Ph.D. (ImQuest BioSciences) – “The Importance and Role of Formulation in Antiviral Drug Development Programs”
Eric Lefebvre, M.D. (Tobira Therapeutics) – “Cenicriviroc, a Novel, Once-daily, Potent Dual CCR5 and CCR2 Antagonist Under Investigation for Treatment of HIV Infection”
- Panel Discussion**
- 4:00pm-6:30pm **Keynote Address:** "Know thine enemy: Using virology and immunology to develop a multifaceted approach to dengue antivirals"
Keynote Speaker: Eva Harris, Ph.D. – Professor of infectious diseases at UC Berkeley, and President of the Sustainable Sciences Institute.
- 6:30pm-8:30pm **Opening Reception**

Sunday, May 12, 2013

- 8:00am-12:00pm **Oral Session I:** Mini-Symposium: “Legacy of Tony Holy: Nucleotides in the Treatment and Prevention of Chronic Viral Infections”
Erik DeClercq, Ph.D., M.D. (Rega Institute) –Personal note on the contributions and legacy of Tony Holy.
John Martin, Ph.D. (Gilead) –Keynote Talk: A tribute to Antonin Holy
Robert Schooley, M.D. (UCSD) – “Tenofovir in the treatment of HIV infection.”
Robert Grant, M.D. (UCSF) – “Tenofovir in the prevention of HIV infection.”
Break
10:30am-11:00am **Henry Chan, Ph.D.** – “Nucleotide analogue in chronic Hepatitis B – from hope to reality”
11:00am-11:30am **Richard Whitley, M.D.** (UAB) – “Nucleotides in the treatment and prophylaxis of herpes and other DNA virus infection.”
11:30am– 12:00pm **Tomas Cihlar, Ph.D.** (Gilead) – “Future potential and therapeutic opportunities for nucleoside phosphonates.”
Lunch on your own
1:30pm-2:15pm **Gertrude Elion Award Lecture**
2:15pm-4:15pm **Oral Session II:** Hepatitis Viruses
Abstract Speakers
4:15pm-6:15pm **Poster Session I:** Retroviruses, Hepatitis Viruses, Respiratory Viruses and Antiviral Methods
6:15pm **New Member and First Time Attendee Networking Event**

Monday, May 13, 2013

- 8:00am-8:45am **William Prusoff Young Investigator Award**
Oral Session III: Mini Chemistry Symposium– Strategies and tactic in Drug Design
8:45am– 9:15am **Ernesto Freire, Ph.D.** (John Hopkins) – “A thermodynamic approach to the development of novel antivirals”
9:15am– 9:45am **Daniel Cheney, Ph.D.** (Bristol Myers Squibb) – “Molecular recognition in drug design”
Break
10:15am– 10:45am **Andrew Woodhead, Ph.D.** (Astex) – “Discovery of a novel allosteric inhibitor of the HCV NS3/4a protein using fragment screening and structure-based design”
10:45am – 11:15am **John Kadow, Ph.D.** (Bristol Myers Squibb) - “The Discovery of an Allosteric NS5B Replicase Inhibitor for the Treatment of Hepatitis C Virus Infection”
11:15am – 11:45am **Nigel Liverton, Ph.D.** (Merck) – “Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor”
Lunch on your own
1:30pm-4:30pm **Oral Session IV:** Respiratory and Emerging Viruses
1:30pm-2:00pm **Bruno Canard, Ph.D.** – “RNA Synthesis, Capping and Repair in (+)RNA Viruses: Novel Targets for Drug Design”
2:00pm–4:30pm **Abstract Speakers**
4:30pm-6:00pm **Poster Session II:** Herpesviruses, Poxviruses, Other Antiviral Agents and Medicinal Chemistry
- Career Happy Hour**

Tuesday, May 14, 2013

- 8:30am-12:00pm **Oral Session V:** Herpesviruses, Poxviruses, Other Antiviral Agents
Abstract Speakers
12:00pm-2:00pm **Women in Science Roundtable*:** This session will address the challenges and opportunities encountered by female scientists while navigating the twists and turns of career progression in today's environment. Come talk to scientists in the industry, government and academic fields.
*Please note registration is limited for this event due to room capacity. Please monitor the website for further registration instructions.
12:00pm **Networking Afternoon**

Wednesday, May 15, 2013

- 8:00am-12:00pm **Oral Session VI:** Mini Chemistry Symposium– Prodrugs as a tool in Drug Discovery and Development.
8:30am – 9:00am **Valentino Stella, Ph.D.** (University Kansas) - "A case for prodrugs"
9:00am – 9:30am **Randall Lanier, Ph.D.** (Chimerix) - “Rational design of nucleoside phosphonates for intracellular delivery using lipid conjugation”
9:30am – 10:00am **John Kadow, Ph.D.** (Bristol Myers Squibb) - “Successful application of phosphate prodrug methodology to an HIV attachment inhibitor for the treatment of HIV-1 infection”
Break
10:30am – 11:00am **Richard Mackman, Ph.D.** (Gilead Sciences) - “Design and SAR of amidate prodrugs for acyclic and cyclic nucleoside phosphonate antivirals – the discovery of GS-7340 and GS-9131”
11:00am – 11:30am **Mike Sofia, Ph.D.** (OnCore Biopharma) – “Prodrugs of nucleosides and nucleotides for the treatment of HCV infection – an overview”
Lunch on your own
1:00pm-3:00pm **Oral Session VII:** Clinical Symposium
Hetal Kocinsky, MD., Clinical Development of Sovaprevir and ACH-3102: Two 2nd Generation Direct-Acting Anti-HCV Agents
Amy Patick, Ph.D. - "Preclinical and clinical studies of miravirsin, a novel anti-HCV therapeutic targeting the host factor miR-122"
3:00pm-5:00pm **Oral Session VIII:** Late Breaker and Shotgun Poster Presentations
Abstract and Poster Speakers
7:30pm-9:30pm **Closing Banquet**